Rosemarie C
Biotechnology
Targovax
Norway
Biography
Ms Rosemarie joined Nordic Nanovector in December 2017 as chief quality officer with overall responsibility for quality assurance (QA) and compliance. Ms Corrigan brings over 25 years of experience in global quality and compliance at pharmaceutical, biotechnology and clinical research organisations, spanning product life cycle from discovery to commercialisation. In her most recent role, Ms Corrigan held the position of global head of QA and alliance manager at the biopharmaceutical company ThromboGenics NV, supporting its products through development, launch and commercialisation. Prior to that, Ms Corrigan was vice president, global quality at Norgine, a European specialty pharma company, where she was responsible for development, manufacturing and supply, commercial and corporate compliance. Ms Corrigan worked for over 10 years at Stiefel International (a skincare company and now part of GlaxoSmithKline), where she was an executive director and led global R&D QA and compliance. Ms Rosemarie joined Nordic Nanovector in December 2017 as chief quality officer with overall responsibility for quality assurance (QA) and compliance. Ms Corrigan brings over 25 years of experience in global quality and compliance at pharmaceutical, biotechnology and clinical research organisations, spanning product life cycle from discovery to commercialisation. In her most recent role, Ms Corrigan held the position of global head of QA and alliance manager at the biopharmaceutical company ThromboGenics NV, supporting its products through development, launch and commercialisation. Prior to that, Ms Corrigan was vice president, global quality at Norgine, a European specialty pharma company, where she was responsible for development, manufacturing and supply, commercial and corporate compliance. Ms Corrigan worked for over 10 years at Stiefel International (a skincare company and now part of GlaxoSmithKline), where she was an executive director and led global R&D QA and compliance.
Research Interest
Pharmaceutics